IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion

Clinical Immunology

Volumn 156, Issue 1, 2015, Pages 58-64

  Abraham, Sojan ^a   Choi, Jang gi ^a   Ye, Chunting ^a   Manjunath, N ^a   Shankar, Premlata ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

GVHD; ; IL 10:; NSG mice; PBMCs;

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 10 RECEPTOR BLOCKING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LETHALITY; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; MOUSE; MOUSE MODEL; NOD SCID GAMMA MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SURVIVAL TIME; T LYMPHOCYTE; ANIMAL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; XENOGRAFT;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HETEROGRAFTS; HUMANS; INTERLEUKIN-10; MICE; MICE, INBRED NOD; MODELS, ANIMAL; T-LYMPHOCYTES;

EID: 84912099098     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.11.004     Document Type: Article

References (26)

1. Paczesny S., Hanauer D., Sun Y., Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010, 45:1-11.
2. Abraham S., Pahwa R., Ye C., Choi J.G., Pahwa S., Jaggaiahgari S., Raut A., Chen S., Manjunath N., Shankar P. Long-term engraftment of human natural T regulatory cells in NOD/SCID IL2rgammac(null) mice by expression of human IL-2. PLoS One 2012, 7:e51832.
3. Blazar B.R., Taylor P.A., Smith S., Vallera D.A. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995, 85:842-851.
4. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Narula S.K., Smith S.R., Roncarolo M.G., Vallera D.A. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 1998, 66:1220-1229.
5. Rowe V., Banovic T., MacDonald K.P., Kuns R., Don A.L., Morris E.S., Burman A.C., Bofinger H.M., Clouston A.D., Hill G.R. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006, 108:2485-2492.
6. Hempel L., Korholz D., Nussbaum P., Bonig H., Burdach S., Zintl F. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant. 1997, 20:365-368.
7. Lin M.T., Storer B., Martin P.J., Tseng L.H., Gooley T., Chen P.J., Hansen J.A. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N. Engl. J. Med. 2003, 349:2201-2210.
8. Holler E., Roncarolo M.G., Hintermeier-Knabe R., Eissner G., Ertl B., Schulz U., Knabe H., Kolb H.J., Andreesen R., Wilmanns W. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000, 25:237-241.
9. Yeh S.P., Liao Y.M., Lo W.J., Lin C.L., Bai L.Y., Lin C.Y., Hsieh C.Y., Chang Y.C., Huang Y.T., Chiu C.F. Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. PLoS One 2012, 7:e44416.
10. Miura Y., Thoburn C.J., Bright E.C., Chen W., Nakao S., Hess A.D. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood 2002, 100:2650-2658.
11. Liu F., Song Y., Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999, 6:1258-1266.
12. Ali N., Flutter B., Sanchez Rodriguez R., Sharif-Paghaleh E., Barber L.D., Lombardi G., Nestle F.O. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One 2012, 7:e44219.
13. King M., Pearson T., Shultz L.D., Leif J., Bottino R., Trucco M., Atkinson M.A., Wasserfall C., Herold K.C., Woodland R.T., Schmidt M.R., Woda B.A., Thompson M.J., Rossini A.A., Greiner D.L. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin. Immunol. 2008, 126:303-314.
14. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
15. Ayala A., Chung C.S., Song G.Y., Chaudry I.H. IL-10 mediation of activation-induced TH1 cell apoptosis and lymphoid dysfunction in polymicrobial sepsis. Cytokine 2001, 14:37-48.
16. Matsuda T., Saito H., Fukatsu K., Han I., Inoue T., Furukawa S., Ikeda S., Hidemura A. Cytokine-modulated inhibition of neutrophil apoptosis at local site augments exudative neutrophil functions and reflects inflammatory response after surgery. Surgery 2001, 129:76-85.
17. Wang Z.Q., Bapat A.S., Rayanade R.J., Dagtas A.S., Hoffmann M.K. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 2001, 102:331-337.
18. Levy Y., Brouet J.C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest. 1994, 93:424-428.
19. Weber-Nordt R.M., Henschler R., Schott E., Wehinger J., Behringer D., Mertelsmann R., Finke J. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996, 88:2549-2558.
20. Godfrey W.R., Spoden D.J., Ge Y.G., Baker S.R., Liu B., Levine B.L., June C.H., Blazar B.R., Porter S.B. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005, 105:750-758.
21. Jenkins C., Garcia W., Godwin M.J., Spencer J.V., Stern J.L., Abendroth A., Slobedman B. Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J. Virol. 2008, 82:3736-3750.
22. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
23. Ding L., Shevach E.M. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J. Immunol. 1992, 148:3133-3139.
24. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 146:3444-3451.
25. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., Thompson-Snipes L., Leach M.W., Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 1996, 98:1010-1020.
26. Emmerich J., Mumm J.B., Chan I.H., LaFace D., Truong H., McClanahan T., Gorman D.M., Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012, 72:3570-3581.